OABI · CIK 1846253
What OmniAb, Inc. told the SEC could break it.
OmniAb's risks reflect a discovery-platform company dependent on a few sites, a few partners, and outside hosts for its core biology. Its research is concentrated at three facilities — Emeryville, California; Durham, North Carolina; and Tucson, Arizona — that a fire, earthquake or power loss could render inoperable, and its revenue leans on a handful of pharma partners, with three each topping 10% of revenue in 2025 (about 15%, 12% and 10%), so losing a major partner program would bite. The transgenic mice and rats at the heart of its platform are hosted by third parties — it owns no vivarium of its own — so underperformance by those hosts could delay or impair its programs and partnerships.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Climate & physical
- Disaster exposure of R&D facilities (Emeryville CA, Durham NC, Tucson AZ)medium
R&D and testing are concentrated at facilities in Emeryville, California; Durham, North Carolina; and Tucson, Arizona that could be rendered inoperable by fire, earthquake, power loss, or other disasters, jeopardizing research efforts.
“Our scientific and engineering research and development and testing is conducted at our facilities located in Emeryville, California, Durham, North Carolina, and Tucson, Arizona. Our facilities and equipment could be harmed or rendered inoperable or inaccessible by natural or man-made disasters or other circumstances beyond our control, including fire, earthquake, power loss”
SEC filing →As of 2026
Customer concentration
- Several partners each >10% of revenuemedium
Revenue is concentrated in a handful of pharma partners — in 2025 three partners were ~15%, 12%, and 10% of revenue (in 2024 three others were 19%, 16%, and 13%) — so loss of a major partner program would materially affect revenue.
“Revenue from significant partners, which is defined as 10% or more of total revenue, was as follows: Year Ended December 31, 2025 2024 Partner A 15 % 12 % Partner B 12 %”
SEC filing →As of 2026
Supplier concentration
- Reliance on third parties to host its mouse/rat colonies (no owned vivarium)medium
OmniAb's core platform is its proprietary transgenic animals, yet it owns no vivarium facilities and relies on third parties to host its mouse and rat colonies; underperformance by those hosts could delay or impair its partnerships and R&D.
“We rely on third parties to host our mouse and rat colonies, and these third parties may not perform satisfactorily which could delay, prevent or impair our partnerships, programs and research and technology development efforts. We do not own or operate vivarium facilities for our mouse and rat colonie”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch